Literature DB >> 33971325

Chondrosarcoma of the spine: a narrative review.

Zach Pennington1, Jeff Ehresman2, Patricia D Pittman3, A Karim Ahmed4, Daniel Lubelski4, Edward F McCarthy5, C Rory Goodwin6, Daniel M Sciubba7.   

Abstract

Chondrosarcoma is an uncommon primary bone tumor with an estimated incidence of 0.5 per 100,000 patient-years. Primary chondrosarcoma of the mobile spine and sacrum cumulatively account for less than 20% of all cases, most .commonly causing patients to present with focal pain with or without radiculopathy, or myelopathy secondary to neural element compression. Because of the rarity, patients benefit from multidisciplinary care at academic tertiary-care centers. Current standard-of-care consists of en bloc surgical resection with negative margins; for high grade lesions adjuvant focused radiation with ≥60 gray equivalents is taking an increased role in improving local control. Prognosis is dictated by lesion grade at the time of resection. Several groups have put forth survival calculators and epidemiological evidence suggests prognosis is quite good for lesions receiving R0 resection. Future efforts will be focused on identifying potential chemotherapeutic adjuvants and refining radiation treatments as a means of improving local control.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Chondrosarcoma; Clinical guidelines; En bloc resection; Evidence-based medicine; Overall survival; Proton beam therapy; Stereotactic radiation

Mesh:

Year:  2021        PMID: 33971325     DOI: 10.1016/j.spinee.2021.04.021

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  2 in total

1.  Chondrosarcoma of the spine-a case report.

Authors:  Sebastian Simon; Heinrich Resch; Friedrich Lomoschitz; Bernhard J H Frank; Roland Kocijan
Journal:  Wien Med Wochenschr       Date:  2022-02-04

Review 2.  Primary Skull Base Chondrosarcomas: A Systematic Review.

Authors:  Paolo Palmisciano; Ali S Haider; Mohammadmahdi Sabahi; Chibueze D Nwagwu; Othman Bin Alamer; Gianluca Scalia; Giuseppe E Umana; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Kenny Yu; Omar N Pathmanaban
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.